Johnson & Johnson (JNJ)
๐ Investor Picks
์ฃผ์ ์ฐจํธ ์ ๋๋น๊ธฐ 300์ !:17๋
์ ์ฃผ์ํฌ์ ๋
ธํ์ฐโฆ๋ก์ผ
24,300์
2026 ์ฃผ์ํฌ์ ๋ฌด์์ ๋ฐ๋ผํ๊ธฐ ๊ฐ์ ํ๋ก์ผ
22,500์
์ฃผ์ ํฌ์ ๋ฌด์์ ๋ฐ๋ผํ๊ธฐ 2026 ( 100๋ง ์์ด๋ณดโฆ๋ก์ผ
22,500์
์ด ํฌ์คํ
์ ์ฟ ํก ํํธ๋์ค ํ๋์ ์ผํ์ผ๋ก, ์ด์ ๋ฐ๋ฅธ ์ผ์ ์ก์ ์์๋ฃ๋ฅผ ์ ๊ณต๋ฐ์ต๋๋ค.
๐ Key Financial Highlights
Revenue
$18.47B
2026-03-29
Net Income
$5.24B
2026-03-29
EPS (Basic)
$2.14
Per share
Total Assets
$200.89B
Balance sheet
Operating Cash Flow
$2.51B
Cash flow statement
Gross Margin
86.4%
Profitability
๐ Filing Information
| Company | Johnson & Johnson |
| Ticker | JNJ |
| Form Type | 10-Q |
| Period of Report | 2026-03-29 |
| Filing Date | 2026-04-22 |
| Sector | Healthcare |
| CIK Number | 0000200406 |
๐ Finance Books
์ฃผ์ํฌ์๋ ์ฌ์ดํด์ด๋ค:39์ธ ์๊ธ์์ด ๋ถ์๊ฐ 20๋
ํฌโฆ๋ก์ผ
18,900์
ํฌ์์ ์ฌ๋ฆฌ:ํ๋๊ฒฝ์ ํ์ผ๋ก ๋ฐฐ์ฐ๋ ์ฌ๋ฆฌํฌ์ ์์
20,700์
๋ถ์๋๊ธฐ ABC
25,000์
์ด ํฌ์คํ
์ ์ฟ ํก ํํธ๋์ค ํ๋์ ์ผํ์ผ๋ก, ์ด์ ๋ฐ๋ฅธ ์ผ์ ์ก์ ์์๋ฃ๋ฅผ ์ ๊ณต๋ฐ์ต๋๋ค.
๐ Filing Summary
This is a Quarterly Report (10-Q) filed by Johnson & Johnson with the SEC. It covers the quarter ending 2026-03-29 and includes unaudited financial statements and management discussion.
Johnson & Johnson (JNJ) operates in the Healthcare sector. The company reported revenue of $18.47B and net income of $5.24B for the period ending 2026-03-29. The filing was submitted to the Securities and Exchange Commission (SEC) on 2026-04-22.
Investors and analysts use 10-Q filings to assess financial health, identify trends, and make investment decisions. Key areas to review include revenue growth, profit margins, cash flow generation, and management's outlook.
๐ Explore More on emfls.com
Discover more financial analysis and guides: